Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its subsidiary, Foshan Fosun Chancheng Hospital, will acquire the remaining equity in a target company for RMB131,146 in cash, increasing its stake to 100%. This transaction, connected through the company’s controlling shareholder, falls under the reporting and announcement requirements of the Hong Kong Listing Rules but does not require independent shareholder approval.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
